2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1573

Major Histocompatibility Antigen HLA-DQ6.1 (DQA1*0103/DQB1*0601) Increases Rheumatoid Arthritis Risk Independent of Shared Epitope Among Indians
Abstract Number: 2878

Major Lymphocyte Populations Share a Common Interferon Signature but Express Cell Type-Specific Interferon Pathway Genes in SLE
Abstract Number: 2503

Making Room for RA Patient Symptoms into Treatment Decision: A Physician Perspective Study
Abstract Number: 2020

Making the Case for Self-Management Education: Marketing Lessons Learned from Qualitative Research
Abstract Number: 239

Malignancies in Korean Patients with Immunoglobulin G4-Related Disease
Abstract Number: 1953

Management and Outcomes of ANCA-Associated Vasculitis in Unselected Cases within a Large Health Region of England
Abstract Number: 1310

Management of Chronic Post-Chikungunya Rheumatic Disease: The Martinican Experience
Abstract Number: 2305

Mapping the Topography of Gout Flares: Solutions for Flare Reporting in Gout Clinical Trials
Abstract Number: 1616

Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-α Monoclonal Antibody: Long-Term Safety and Efficacy for up to 158 Weeks of Treatment in Patients with Rheumatoid Arthritis
Abstract Number: 2732

Meaningful Involvement of Patients in the Development of a Core Outcome Set for Psoriatic Arthritis
Abstract Number: 757

Measures of Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus (SLE): Results from a Two-Part 52 Week Pilot Study of Repository Corticotropin Injection (H.P. Acthar® Gel)
Abstract Number: 138

Measuring Agreement in the Ultrasonographic Evaluation of Disease Activity in Rheumatoid Arthritis Patients. a Latin-American Multicenter Exercise Assessing the Influence of Sonographer Experience and Expertise
Abstract Number: 1989

Mechanism of STAT3 Gain-of-Function in a Patient with JIA
Abstract Number: 2429

Mechanisms for the Development of Lung Fibrosis in Sting-Associated Vasculopathy with Onset in Infancy (SAVI)
Abstract Number: 2927

Mechanisms Regulating the Loss of Tregs in CD11c-Flip-KO Mice That Contribute to the Spontaneous Development of Inflammatory Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].